Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Centogene N.V.
(NQ:
CNTG
)
0.3250
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Centogene N.V.
< Previous
1
2
3
4
5
Next >
CENTOGENE Receives Delisting Notice From Nasdaq
August 07, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
August 01, 2024
From
Centogene NV
Via
GlobeNewswire
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
June 20, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
May 31, 2024
From
Centogene NV
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 16, 2024
Pre-market stock movers are a hot topic on Thursday and we have them covered with our breakdown of all the latest news this morning!
Via
InvestorPlace
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
May 15, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
May 15, 2024
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
May 14, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
May 10, 2024
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations
From
Centogene NV
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
April 19, 2024
Friday is here and we're breaking down the biggest pre-market stock movers that traders need to know about this morning!
Via
InvestorPlace
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
April 19, 2024
Via
Benzinga
CENTOGENE Receives Nasdaq Non-Compliance Notice
April 02, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
February 29, 2024
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
February 28, 2024
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Explores Strategic Alternatives
February 28, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
January 25, 2024
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives French Research Tax Credit Accreditation
January 24, 2024
Partners able to claim up to 30% tax relief
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
January 23, 2024
Collaboration to accelerate research to determine role of GBA gene
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Preliminary Full Year 2023 Revenue
January 18, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 19, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
December 13, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
November 28, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
November 14, 2023
Results From Landmark Study Published in Brain Journal
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
October 10, 2023
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports First Half 2023 Financial Results
September 07, 2023
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
September 01, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
August 31, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in August
August 07, 2023
From
Centogene NV
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.